Literature DB >> 23307118

Birt-Hogg-Dubé syndrome and the skin.

Marigje Vernooij1, Tijs Claessens, Monique Luijten, Maurice A M van Steensel, Barry J Coull.   

Abstract

Birt-Hogg-Dubé syndrome (MIM #135150) is characterized by the development of benign skin tumours called fibrofolliculomas, pulmonary cysts that may lead to pneumothorax and a high risk of developing kidney cancer. BHD is caused by mutations affecting the highly conserved protein folliculin (FLCN), which probably has a role in intracellular transport. Most of the research effort directed towards BHD has focused on understanding how loss of FLCN causes kidney cancer. The cutaneous manifestations have received comparatively little attention. Although understandable, it is unfortunate, as the fibrofolliculomas are highly accessible and thus potentially are an excellent system for trying to understand the basic pathobiology of BHD. Also, patients can be very much burdened by the cosmetic consequences of having hundreds of facial skin tumours. Our lack of insight into what drives fibrofolliculoma growth translates into a very limited therapeutic arsenal. Thus, paying attention to fibrofolliculomas has both basic science and practical benefits. In this review, we will discuss the state of the art regarding our understanding of fibrofolliculoma pathogenesis and indicate future directions for research.

Entities:  

Mesh:

Year:  2013        PMID: 23307118     DOI: 10.1007/s10689-013-9600-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  30 in total

1.  Treatment of Birt-Hogg-Dubé syndrome with erbium:YAG laser.

Authors:  T Gambichler; M Wolter; P Altmeyer; K Hoffman
Journal:  J Am Acad Dermatol       Date:  2000-11       Impact factor: 11.527

2.  Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility.

Authors:  Raymond A Cocciolone; Kerry A Crotty; Lesley Andrews; Nikolas K Haass; Fergal J Moloney
Journal:  Arch Dermatol       Date:  2010-11

3.  [Multiple mantleomas in Birt-Hogg-Dubé syndrome: successful therapy with CO2 laser].

Authors:  B Kahle; S Hellwig; T Schulz
Journal:  Hautarzt       Date:  2001-01       Impact factor: 0.751

4.  Identification of novel target proteins in sebaceous gland carcinoma.

Authors:  Boban M Erovic; Ayman Al Habeeb; Luke Harris; David P Goldstein; Dae Kim; Danny Ghazarian; Jonathan C Irish
Journal:  Head Neck       Date:  2012-06-19       Impact factor: 3.147

5.  Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis.

Authors:  Shaowei Li; Rajesh L Thangapazham; Ji-An Wang; Sangeetha Rajesh; Tzu-Cheg Kao; Leonard Sperling; Joel Moss; Thomas N Darling
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

6.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

7.  The Birt-Hogg-Dubé tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis.

Authors:  Kriti Gaur; Jinghong Li; Dakun Wang; Pranabananda Dutta; Shian-Jang Yan; Amy Tsurumi; Hartmut Land; Guan Wu; Willis X Li
Journal:  Hum Mol Genet       Date:  2012-10-16       Impact factor: 6.150

8.  Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis.

Authors:  Michael S Nahorski; Laurence Seabra; Ania Straatman-Iwanowska; Aileen Wingenfeld; Anne Reiman; Xiaohong Lu; Jeff A Klomp; Bin T Teh; Mechthild Hatzfeld; Paul Gissen; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

9.  Letter: hyfrecation and curettage as a treatment for fibrofolliculomas in Birt-Hogg-Dube syndrome.

Authors:  Paul B J Farrant; Russell Emerson
Journal:  Dermatol Surg       Date:  2007-10       Impact factor: 3.398

10.  Fibrofolliculoma: a clinicopathologic study.

Authors:  K Foucar; T Rosen; E Foucar; R J Cochran
Journal:  Cutis       Date:  1981-10
View more
  7 in total

Review 1.  Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  The Birt-Hogg-Dubé cancer predisposition syndrome: Current challenges.

Authors:  Patrick R Benusiglio
Journal:  Intractable Rare Dis Res       Date:  2015-08

3.  Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Expert Opin Orphan Drugs       Date:  2014-11-29       Impact factor: 0.694

Review 4.  Birt-Hogg-Dubé syndrome: a literature review and case study of a Chinese woman presenting a novel FLCN mutation.

Authors:  Shengyu Hao; Fei Long; Fenglan Sun; Teng Liu; Daowei Li; Shujuan Jiang
Journal:  BMC Pulm Med       Date:  2017-02-21       Impact factor: 3.317

5.  Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.

Authors:  Ernst Näf; Dominik Laubscher; Helmut Hopfer; Markus Streit; Gabor Matyas
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

6.  Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial.

Authors:  Lieke M C Gijezen; Marigje Vernooij; Herm Martens; Charlene E U Oduber; Charles J M Henquet; Theo M Starink; Martin H Prins; Fred H Menko; Patty J Nelemans; Maurice A M van Steensel
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

7.  Delayed diagnosis of Birt-Hogg-Dubé syndrome due to marked intrafamilial clinical variability: a case report.

Authors:  E C Sattler; O K Steinlein
Journal:  BMC Med Genet       Date:  2018-03-16       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.